PRTT Protect Pharmaceutical Corp

Protect Pharmaceutical Commences Production of a New Kind of Green: Cannabis-Based “Green Wine”

Protect Pharmaceutical Commences Production of a New Kind of Green: Cannabis-Based “Green Wine”

Sevnica, Slovenia, May 28, 2020 (GLOBE NEWSWIRE) -- Protect Pharmaceutical Corp. “OTC:(PRTT)” Protect Pharmaceutical Corp is excited to announce the commencement of its production of cannabis-based wine, also known as “Green Wine,” on its Mastnak Winery fields in Slovenia. The production will be done in cooperation with the Slovenian division of Rafarma Pharmaceuticals, Inc. (OTC ticker: RAFA).

Mastnak Winery will dedicate approximately 25% of its 2020 production of non-sparkling white wine to produce the initial run of Green Wine (approximately 200,000 bottles). The barrels will be prepared during the 2020 harvesting season. The first bottles will be available for sale in the fall of 2021.

All Mastnak Winery grapes are currently grown utilizing the company’s proprietary “Super Fertilizer” known as Agropharmacy—a completely organic growth stimulant.

The cannabis for the Green Wine, which contains Tetrahydrocannabinol (THC), will be supplied by Rafarma Pharmaceuticals, Inc. (OTC ticker: RAFA). During the production process, dried cannabis wrapped in white cloth will be inserted into barrels of white wine (about 1/2 kilogram per barrel). Two types of cannabis, Sativa and Indica, will be aged in casks for a year. Rafarma Pharmaceuticals uses the biologically-clean Agropharmacy products for its production of cannabis as well.

Green wine is known to help its consumers relax more than with the standard wine. It has also been shown to aid in treating insomnia. The introduction of Green Wine is yet another exciting step in the company’s European expansion. Green Wine is expected to be in great demand, and could increase revenue per bottle substantially.

Forward-Looking Statements: This press release contains “forward-looking statements” within the meaning of Section 21E of the Securities Exchange Act of 1934. Except for historical matters contained herein, statements made in this press release are forward-looking statements. Without limiting the generality of the foregoing, words such as “may”, “will”, “to”, “plan”, “expect”, “believe”, anticipate”, “intend”, “could”, “would”, “estimate,” or “continue”, or the negative other variations thereof or comparable terminology are intended to identify forward-looking statements. Forward-looking statements involve known and unknown risk, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Also, forward-looking statements represent our management’s beliefs and assumptions only as of the date hereof. Additional information regarding the factors that may cause actual results to differ materially from these forward-looking statements is available in the Company's filings with OTC Markets. Except as required by law, we assume no obligation to update these forward-looking statements publicly or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.

For more information contact:

Protect Pharmaceutical Corp.

(801) 432-0405

Attachment

EN
28/05/2020

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Protect Pharmaceutical Corp

 PRESS RELEASE

Ali Yildiz December 29, 2023 Letter to the Shareholders of Protect Pha...

Ali Yildiz December 29, 2023 Letter to the Shareholders of Protect Pharmaceutical Corp. Istanbul, Turkey, Dec. 29, 2023 (GLOBE NEWSWIRE) -- Protect Pharmaceutical Corp. “OTC:(PRTT)” Ali Yildiz Addresses shareholders of the company. We wanted to update shareholders in regards to the progress on our PCAOB Audit. We had a small delay that originated from the auditor needing physical access to a secure facility that houses customs products. We believe the delay will be minimal and are still on track to finalize our audit within the next week to two weeks. We apologize for the unforeseen dela...

 PRESS RELEASE

Ali Yildiz December 22, 2023 Letter to the Shareholders of Protect Pha...

Ali Yildiz December 22, 2023 Letter to the Shareholders of Protect Pharmaceutical Corp. Istanbul, Turkey, Dec. 22, 2023 (GLOBE NEWSWIRE) -- Protect Pharmaceutical Corp. “OTC:(PRTT)” Ali Yildiz Addresses shareholders of the company. As we stated last week we are in the final stages of our PCAOB audit and expect its completion very soon. We have now responded to the open items to the auditor. We expect to receive the finalized audit report very soon and feel we can still meet our goal of completion before year end. As we end the year we are optimistic and believe that the company has accom...

 PRESS RELEASE

Protect Pharmaceutical Corp. CEO Provides Shareholder Update

Protect Pharmaceutical Corp. CEO Provides Shareholder Update Istanbul, Turkey, Dec. 15, 2023 (GLOBE NEWSWIRE) -- Protect Pharmaceutical Corp. “OTC:(PRTT)” Protect Pharmaceutical Corp. CEO Ali Yildiz Provides Shareholder Update. As CEO of PRTT I wanted to update shareholders on current progress within the company. We posted our largest quarter for revenues for the second consecutive quarter. Our growth strategy is working and we recently announced the acquisition of Bosfor Export. This is one of several acquisition targets and we plan to continue to grow and expand not only our curr...

 PRESS RELEASE

Protect Pharmaceutical Corp. Acquires Bosfor Export

Protect Pharmaceutical Corp. Acquires Bosfor Export Istanbul, Turkey, Nov. 24, 2023 (GLOBE NEWSWIRE) -- Protect Pharmaceutical Corp. “OTC: PRTT” is pleased to announce the acquisition of Bosfor Export. This strategic move has been financed through the issuance of 2,000,000 restricted shares, representing 100% ownership of Bosfor Export. Bosfor Export, known for its robust fruit wholesaling operations in Istanbul, currently achieves an annual revenue of approximately $28 million USD. With this acquisition, PRTT's management is optimistic about significantly increasing revenues by leveragi...

 PRESS RELEASE

Protect Pharmaceutical Corp. CEO Provides Shareholder Update

Protect Pharmaceutical Corp. CEO Provides Shareholder Update Istanbul, Turkey, Sept. 26, 2023 (GLOBE NEWSWIRE) -- Protect Pharmaceutical Corp. “OTC:(PRTT)” Protect Pharmaceutical Corp. CEO Ali Yildiz Provides Shareholder Update. As we enter the 4th quarter we feel the company has entered a very pivotal time in our growth strategy. We posted our largest quarter for revenues in the second quarter of 2023 and our expansion goals and strategies are progressing very nicely. For the 6 months ending June 30, 2023 we had 62 million dollars in revenue with an operating profit of over 18 million...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch